Document Detail

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.
MedLine Citation:
PMID:  18480425     Owner:  NLM     Status:  MEDLINE    
Venous thromboembolism (VTE) is increasingly diagnosed among individuals with hematologic malignancies. However, the risk of VTE among patients undergoing hematopoietic stem cell transplantation (HSCT) is unclear. We examined the incidence and risk factors for VTE and bleeding among 1514 patients undergoing in-patient HSCT. No protocolized VTE prophylaxis was used. By HSCT day 180, 75 symptomatic VTE occurred in 70 patients (4.6%; 95% confidence interval [CI], 3.6%-5.8%). Fifty-five (3.6%) were catheter-associated, 11 (0.7%) were non-catheter-associated deep venous thromboses, and 9 (0.6%) were pulmonary emboli. Thirty-four percent of VTE occurred at a platelet count less than 50 x10(9)/L; 13% occurred at a platelet count less than 20 x10(9)/L. In multivariate analysis, VTE was associated with prior VTE (odds ratio [OR], 2.9; 95% CI, 1.3-6.6) and with graft-versus-host disease (GVHD; OR, 2.4; 95% CI, 1.4-4.0). Clinically significant bleeding occurred in 230 patients (15.2%; 95% CI, 13.4%-17.1%); 55 patients (3.6%; 95% CI, 2.7%-4.7%) had fatal bleeding. Bleeding was associated with anticoagulation (OR, 3.1; 95% CI, 1.8-5.5), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6). In HSCT patients, VTE is primarily catheter-related and 3-fold less common than clinically significant bleeding. These findings warrant consideration when selecting VTE prophylaxis in HSCT patients.
David E Gerber; Jodi B Segal; M Yair Levy; Joyce Kane; Richard J Jones; Michael B Streiff
Related Documents :
3488795 - Distal splenorenal (warren) shunt in the management of actively bleeding oesophageal va...
16537875 - Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy...
10560805 - Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated wit...
16244775 - Clinico-hematologic profile of factor xiii-deficient patients.
2456725 - Persistent gross splenomegaly in nigerian patients with sickle cell anaemia: relationsh...
11786735 - Tc-99m ethylcysteinate dimer brain spect perfusion imaging in ictal nonepileptic visual...
Publication Detail:
Type:  Journal Article     Date:  2008-05-14
Journal Detail:
Title:  Blood     Volume:  112     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-24     Completed Date:  2008-09-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  504-10     Citation Subset:  AIM; IM    
Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / adverse effects
Catheterization / adverse effects
Cohort Studies
Hematopoietic Stem Cell Transplantation / adverse effects*
Hemorrhage / etiology*
Middle Aged
Retrospective Studies
Risk Factors
Venous Thromboembolism / etiology*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalasse...
Next Document:  Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and pla...